Full Press Release Details
IDEAYA and Amgen Achieve First Patient In for Clinical Evaluation of IDE397 MAT2A and AMG 193 PRMT5 MTA Combination in MTAP Tumors.
IDYA
IDEAYA and Amgen Achieve First Patient In for Clinical Evaluation of IDE397 MAT2A and AMG 193 PRMT5 MTA Combination in MTAP Tumors
Key Takeaway: IDEAYA and Amgen Achieve First Patient In for Clinical Evaluation of IDE397 MAT2A and AMG 193 PRMT5 MTA Combination in MTAP Tumors